Soligenix Inc

+0.02 (+2.31%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)38.16M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.22 Million
Adjusted EPS-$0.09
See more estimates
10-Day MA$0.89
50-Day MA$0.99
200-Day MA$1.19
See more pivots

Soligenix Inc Stock, NASDAQ:SNGX

29 Emmons Drive, Suite B-10, Princeton, New Jersey 08540-5919
United States of America
Phone: +1.609.538.8200
Number of Employees: 18


Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.